119 related articles for article (PubMed ID: 10463520)
1. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Clin Ther; 1999 Jul; 21(7):1230-40. PubMed ID: 10463520
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Fuh JL; Wang SJ
Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
López-Bastida J; Hart W; García-Pérez L; Linertová R
J Alzheimers Dis; 2009; 16(2):399-407. PubMed ID: 19221429
[TBL] [Abstract][Full Text] [Related]
4. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model.
Kasuya M; Meguro K
Arch Gerontol Geriatr; 2010; 50(3):295-9. PubMed ID: 19481822
[TBL] [Abstract][Full Text] [Related]
5. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
Fagnani F; Lafuma A; Pechevis M; Rigaud AS; Traykov L; Seux ML; Forette F
Dement Geriatr Cogn Disord; 2004; 17(1-2):5-13. PubMed ID: 14560059
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
8. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.
Teipel SJ; Ewers M; Reisig V; Schweikert B; Hampel H; Happich M
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):330-6. PubMed ID: 17404699
[TBL] [Abstract][Full Text] [Related]
9. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
10. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
11. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
[TBL] [Abstract][Full Text] [Related]
12. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
13. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
[TBL] [Abstract][Full Text] [Related]
15. The effect of donepezil therapy on health costs in a Medicare managed care plan.
Hill JW; Futterman R; Mastey V; Fillit H
Manag Care Interface; 2002 Mar; 15(3):63-70. PubMed ID: 11925682
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Getsios D; Blume S; Ishak KJ; Maclaine GD
Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
19. Donepezil. Pharmacoeconomic implications of therapy.
Foster RH; Plosker GL
Pharmacoeconomics; 1999 Jul; 16(1):99-114. PubMed ID: 10539126
[TBL] [Abstract][Full Text] [Related]
20. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
Passmore AP; Bayer AJ; Steinhagen-Thiessen E
J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
